Skip to Main Content

Author Details

Richard Choo
Mayo Clinic
1991
94
24
PMIDPaper TitleJournal TitlePublished Year
36427645Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36845611Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.Adv Radiat Oncol2022
35652618The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.Prostate2022
35789497A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.Prostate2022
35422402Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy.Brachytherapy2022
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
33636378Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.Pract Radiat Oncol2021
34722810Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity.Int J Part Ther2021
34604551Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer.Clin Transl Radiat Oncol2021
34324914Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.Radiother Oncol2021
31353875Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?Minerva Urol Nefrol2020
32931662Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.Cancer Med2020
32109600Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center.Pract Radiat Oncol2020
31011676Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.Adv Radiat Oncol2019
31788504IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison.Int J Part Ther2019
30050795Low dose rate prostate brachytherapy.Transl Androl Urol2018
31773034Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes.Int J Part Ther2018
32775476Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis.Bladder (San Franc)2018
27597240Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.Eur Urol2017
28462943Media reporting of ProtecT: a disconnect in information dissemination?Prostate Cancer Prostatic Dis2017
28126302Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.Int J Radiat Oncol Biol Phys2017
28576185Brachytherapy in the Management of Prostate Cancer.Surg Oncol Clin N Am2017
26700655Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol2016
27895677Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.J Contemp Brachytherapy2016
27480153Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.J Clin Oncol2016
27542893Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray.Brachytherapy2016
26936410Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.BMJ2016
26825250Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review.Pract Radiat Oncol2016
25927031Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.Front Oncol2015
25903934Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.Radiat Oncol2015
23490907Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience.Urol Oncol2014
24332645Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy.Urol Oncol2014
24411190Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma.Int J Radiat Oncol Biol Phys2014
22537538Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience.Urol Oncol2013
23265571Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.Int J Radiat Oncol Biol Phys2013
22868244Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter.Am J Clin Oncol2013
21237581Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.Int J Radiat Oncol Biol Phys2012
22857860Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer.Radiother Oncol2012
22079736Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.Int J Radiat Oncol Biol Phys2012
21514065Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma.Int J Radiat Oncol Biol Phys2012
21310302Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer.Nutr Res2011
19506916Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function.Support Care Cancer2010
21234257Multiple urinary bladder masses from metastatic prostate adenocarcinoma.Rare Tumors2010
20944793Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?Can Urol Assoc J2010
20369045Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Cancer Res Treat2010
19211197Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.Int J Radiat Oncol Biol Phys2009
19409726Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.Int J Radiat Oncol Biol Phys2009
18436391Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.Int J Radiat Oncol Biol Phys2008
19046556High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer.Mayo Clin Proc2008
18710743Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.J Urol2008
  • 1 - 50 of 94

Recommended Authors

William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 36
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 6
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 9
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 5
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 4
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 18
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 3
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 19
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 25
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 1
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 27
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 27
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 13
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 3
Alan W Katz
University of Rochester
Career Start Year 1996
Number of shared co-authors 16
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 19
Almudena Zapatero
University Hospital La Princesa
Career Start Year 1995
Number of shared co-authors 48
Laurence Collette
Belgium International Drug Development Institute
Career Start Year 1995
Number of shared co-authors 13
Xavier Maldonado
Hospital Universitari Vall d'Hebron
Career Start Year 1994
Number of shared co-authors 47
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 27
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 13
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 51
Jeff M Michalski
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 36
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 17
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 39
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 16
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 14
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 34
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 10
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 25

Collaborators

Brian J Davis
Mayo Clinic
Co-authored papers 25
Thomas M Pisansky
Mayo Clinic
Co-authored papers 18
Bradley J Stish
Mayo Clinic
Co-authored papers 16
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Co-authored papers 15
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 7
Neil E Fleshner
University of Toronto
Co-authored papers 6
Rafael Mart??nez-Monge
Clinica Universitaria de Navarra
Co-authored papers 2
Michael Brundage
Cancer Centre of Southeastern Ontario
Co-authored papers 2
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 2
Ridwan Alam
Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 1
Michelle H Braccioforte
Prostate Cancer Foundation of Chicago
Co-authored papers 1
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Co-authored papers 1
Alan H Bryce
Mayo Clinic
Co-authored papers 1
Trude B Wedde
Oslo University Hospital
Co-authored papers 1
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 1
Albert J Chang
University of California Los Angeles
Co-authored papers 1
Ivy A Petersen
Mayo Clinic
Co-authored papers 1
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 1
David Jeffrey Demanes
University of California los angeles
Co-authored papers 1
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Zeyad R Schwen
Glickman Urological & Kidney Institute, Cleveland Clinic
Co-authored papers 1
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 1
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 1
David Shabsovich
university of california los angeles Medical Center
Co-authored papers 1
Elizabeth B Habermann
Department of Health Services Research, Mayo Clinic
Co-authored papers 1
Amar U Kishan
University of California los angeles
Co-authored papers 1
David Elashoff
David Geffen School of Medicine at University of California los angeles
Co-authored papers 1
Parminder Singh
Mayo Clinic
Co-authored papers 1
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 1
Release 1.2